News

WuXi News

Filter By

2015/10/13

WuXi PharmaTech Launches Mobile OncoWuXi, the World's First App for Accessing Oncology Models

SHANGHAI, October 13, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that it has launched a mobile version of OncoWuXi, the first App in the world to allow researchers to access oncology models and data on the go. The OncoWuXi App helps WuXi's clients anywhere and at any time to identify relevant tumor models for use in anti-tumor efficacy testing to facilitate oncology drug discovery and translational oncology, as well as to keep up-to-date on WuXi's capabilities and services in this area.

Read more

2015/09/17

WuXi PharmaTech Receives 2015 Open-Access R&D Technology Leadership Award from Frost & Sullivan

SHANGHAI, September 17, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that it has been awarded the 2015 Frost & Sullivan North American Open-Access R&D Technology Leadership Award. The award is part of Frost & Sullivan's Growth, Innovation & Leadership Award series, recognizing companies that have demonstrated excellence in devising and implementing strong growth strategies.

Read more

2015/08/27

WuXi PharmaTech's STA Subsidiary Receives First Approval from Japanese Regulatory Authorities

SHANGHAI, Aug. 27, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that its small-molecule process development and manufacturing subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA) received its first approval from the Japan PMDA for the manufacture of the GMP intermediate of a branded commercial drug in July. STA is now the only Chinese contract manufacturing organization to have received approval to supply active pharmaceutical ingredients (APIs) and GMP intermediates for branded commercial drugs from regulatory agencies in the United States, Canada, the European Union, Switzerland, China, Japan, Australia, and New Zealand.

Read more

2015/08/26

WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm

SHANGHAI, August 26, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, and Lee's Pharmaceutical Holdings Ltd. ("Lee's Pharm," Hong Kong Exchange Stock Code: 0950), a research-based biopharmaceutical company headquartered in Hong Kong with 20 years of operations in China, today announced that the two companies have signed an agreement whereby WuXi's Laboratory Testing Division (LTD) will be the exclusive supplier of laboratory testing services for Lee's Pharm.

Read more

2015/08/14

Wuxi Pharmatech Enters Into Definitive Merger Agreement

WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with New WuXi Life Science Limited ("Parent") and WuXi Merger Limited ("Merger Sub"), a wholly owned subsidiary of Parent.

Read more